Crispr Therapeutics
在场
Crispr Therapeutics 是一家在股票代码 CRSP (CH) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Crispr Therapeutics 搜索最多的简介
- Samarth Kulkarni, Chief Executive Officer and Chairman of the Board
- Edd Fleming, Director
- Simeon George, Director
高管在Crispr Therapeutics变化
- Christian Rommel已作为Director加入公司 (新闻发布的2024三月14号).
- Phuong Morrow, Chief Medical Officer, 将于 20241月26 退休 (新闻发布的2023十二月22号).
- Sandy MahatmeSandy Mahatme 将于20246月作为 Director 加入公司 (新闻发布的2023十月17号).
创建提醒
跟踪 Crispr Therapeutics 的高管变动
生物技术
Crispr Therapeutics 拥有 2,294 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Lycia Therapeutics 刚刚宣布为 107 筹款数百万美元。 (公布2024五月15号).
- Attovia Therapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2024五月14号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024五月13号).
生物技术 行业的其他推荐联系人
消息
Crispr Therapeutics 的最新新闻稿
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | CRISPR Therapeutics
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Host Innovation Day on June 21, 2022 | CRISPR Therapeutics
- CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies | CRISPR Therapeutics
- CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry | CRISPR Therapeutics
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences | CRISPR Therapeutics
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference | CRISPR Therapeutics
- View more press releases Close
通过电子邮件
